Adverum Biotechnlgs (NASDAQ:ADVM)’s share price plunged -0.8% or -0.05 to reach at $6.2 during previous trading session. A total of 1.18 Million shares exchanged hands, whereas the company’s average trading volume stands at 735.21 Million shares. Adverum Biotechnlgs (NASDAQ:ADVM) has a market capitalization of $426.25 Million and most recently 68.75 Million outstanding shares have been calculated.

According to sentiments of 3 analysts the mean estimates of short term price target for the company’s stock is marked at $10. The most optimistic analyst sees the stock reaching $12 while the most conventional predicts the target price at $8.

In terms of Buy/Sell recommendations, 4 analysts have a consensus rating of 1.75 on the shares of Adverum Biotechnlgs (NASDAQ:ADVM). Out of rating recommendations 0 have given the stock a Buy while 3 recommend the stock as Outperform. 1 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

Adverum Biotechnlgs (NASDAQ:ADVM)’s shares slipped -2.36% in the past week and soared 7.83% in the last 4 weeks, historically the stock illustrate that its six months performance stands at 90.77% while its year to date performance is at 77.14%.

While taking a glance at financials, we can look at a number of key indicators. Adverum Biotechnlgs (NASDAQ:ADVM) has a Return on Assets (ROA) of -26.4. The company currently has a Return on Equity (ROE) of -28.5 and a Return on Investment (ROI) of -26.5. Average true range (ATR-14) of the company sets at 0.38, along with its weekly and monthly volatility of 6.61% and 5.55% respectively. Relative strength index (RSI-14) for Adverum Biotechnlgs (NASDAQ:ADVM) is at 49.02. Beta value of the stock stands at 3.64.

The company’s price to free cash flow for trailing twelve months is 0. Its quick ratio for most recent quarter is 26.9 along with current ratio for most recent quarter of 26.9. Total debt to equity ratio of Adverum Biotechnlgs (NASDAQ:ADVM) for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0.

Shares of Aptose Bioscns Cmn (NASDAQ:APTO) soared 6.39% or 0.26 to reach at $4.33 during previous trading session. Aptose Bioscns Cmn (NASDAQ:APTO) has a market capitalization of $122.37 Million and most recently 28.26 Million outstanding shares have been calculated. A total of 1.03 Million shares exchanged hands, whereas the company’s average trading volume stands at 347.11 Million shares.

According to 1 analysts Aptose Bioscns Cmn (NASDAQ:APTO)’s price will reach at $4.72 during 52 weeks. Stock’s minimum price target estimates has been figured out at $4.72 while the maximum price target forecast is established at $4.72.

According to the recommendations from 2 analysts stock has mean rating of 1 on the shares of Aptose Bioscns Cmn (NASDAQ:APTO). Out of rating recommendations 0 have given the stock a Buy while 1 recommend the stock as Outperform. 0 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

Shares of Aptose Bioscns Cmn (NASDAQ:APTO) climbed 19.94% in the past week and soared 34.06% in the last 4 weeks, historically the stock illustrate that its six months performance stands at 132.17% while its year to date performance is at 93.3%.

Total debt to equity ratio of Aptose Bioscns Cmn (NASDAQ:APTO) for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0. The company’s price to free cash flow for trailing twelve months is 0. Its quick ratio for most recent quarter is 7.5 along with current ratio for most recent quarter of 7.5.

Average true range (ATR-14) of the company sets at 0.16, along with its weekly and monthly volatility of 5.06% and 4.57% respectively. Relative strength index (RSI-14) for Aptose Bioscns Cmn (NASDAQ:APTO) is at 80.58. Beta value of the stock stands at 2.38. Aptose Bioscns Cmn (NASDAQ:APTO) has a Return on Assets (ROA) of 0. The company currently has a Return on Equity (ROE) of 0 and a Return on Investment (ROI) of 0.